Symbols / VRCA
VRCA Chart
About
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 89.38M |
| Enterprise Value | 67.69M | Income | -26.01M | Sales | 30.83M |
| Book/sh | -1.80 | Cash/sh | 2.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 71 | IPO | — |
| P/E | — | Forward P/E | -2.50 | PEG | — |
| P/S | 2.90 | P/B | -3.11 | P/C | — |
| EV/EBITDA | -4.53 | EV/Sales | 2.20 | Quick Ratio | 0.98 |
| Current Ratio | 1.25 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.87 | EPS next Y | -2.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-11 | ROA | -26.28% |
| ROE | — | ROIC | — | Gross Margin | 67.02% |
| Oper. Margin | 11.34% | Profit Margin | -84.38% | Shs Outstand | 15.99M |
| Shs Float | 3.32M | Short Float | 2.85% | Short Ratio | 2.07 |
| Short Interest | — | 52W High | 9.82 | 52W Low | 3.28 |
| Beta | 1.44 | Avg Volume | 255.95K | Volume | 5.96K |
| Target Price | $16.50 | Recom | Strong_buy | Prev Close | $5.59 |
| Price | $5.59 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.50
Mean price target
2. Current target
$5.59
Latest analyst target
3. DCF / Fair value
$-28.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.59
Low
$10.00
High
$20.00
Mean
$16.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-18 | up | Brookline Capital | Hold → Buy | $17 |
| 2025-05-14 | reit | Needham | Hold → Hold | — |
| 2025-04-09 | reit | Needham | Hold → Hold | — |
| 2025-04-08 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-12 | reit | Needham | Hold → Hold | — |
| 2024-12-20 | reit | Needham | Hold → Hold | — |
| 2024-11-06 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-11-05 | reit | Needham | — → Hold | — |
| 2024-11-05 | down | RBC Capital | Outperform → Sector Perform | $2 |
| 2024-10-21 | main | TD Cowen | Buy → Buy | $10 |
| 2024-10-04 | main | RBC Capital | Outperform → Outperform | $11 |
| 2024-10-03 | down | Needham | Buy → Hold | $12 |
| 2024-10-02 | down | Brookline Capital | Buy → Hold | — |
| 2024-08-15 | main | RBC Capital | Outperform → Outperform | $13 |
| 2024-08-15 | main | Needham | Buy → Buy | $12 |
| 2024-05-16 | reit | Needham | Buy → Buy | $16 |
| 2024-05-14 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-05-14 | main | Needham | Buy → Buy | $16 |
| 2024-04-10 | reit | Needham | Buy → Buy | $8 |
| 2024-03-01 | reit | Needham | Buy → Buy | $8 |
- Verrica Pharmaceuticals Stock (VRCA) Opinions on $50 Million Financing Deal - Quiver Quantitative Sun, 30 Nov 2025 08
- Technical Reactions to VRCA Trends in Macro Strategies - Stock Traders Daily Sat, 21 Feb 2026 21
- New molluscum treatment YCANTH reaches Japanese patients after Phase 3 trial - Stock Titan Mon, 09 Feb 2026 08
- Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why - Yahoo Finance Mon, 02 Feb 2026 08
- Verrica Pharmaceuticals Stock 5-Day Winning Spree: Stock Climbs 88% - Trefis ue, 02 Dec 2025 08
- Shareholders May Not Overlook Verrica Pharmaceuticals Insiders Selling US$1.1m In Stock - simplywall.st Fri, 13 Jun 2025 07
- Verrica (NASDAQ: VRCA) Announces $50M PIPE to Retire OrbiMed Debt, Extend Runway to 2027 - Stock Titan Mon, 24 Nov 2025 08
- $VRCA stock is up 20% today. Here's what we see in our data. - Quiver Quantitative Wed, 26 Nov 2025 08
- Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance Mon, 17 Nov 2025 08
- With Verrica Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis Sat, 20 Dec 2025 08
- New wart treatment enters Phase 3 testing for 22M U.S. patients - Stock Titan Wed, 07 Jan 2026 08
- Verrica Pharmaceuticals Reports $14.3 Million in Q3'25 Revenue and Advances Regulatory Programs for YCANTH® and VP-315 - Quiver Quantitative Fri, 14 Nov 2025 08
- Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance Mon, 11 Aug 2025 07
- Verrica (NASDAQ: VRCA) presents VP-315 BCC findings: more T-cell infiltration, fewer Tregs - Stock Titan Mon, 10 Nov 2025 08
- Insider Purchase: CMO of $VRCA Buys 2,357 Shares - Quiver Quantitative Wed, 26 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | KIRBY JOHN J. | Chief Financial Officer | — | 2025-12-23 00:00:00 | D |
| 1 | 94311 | 400114 | — | Purchase at price 4.24 per share. | RIEGER JAYSON | Chief Executive Officer | — | 2025-11-25 00:00:00 | D |
| 2 | 10000 | 42425 | — | Purchase at price 4.24 per share. | ZAWITZ DAVID | Chief Operating Officer | — | 2025-11-25 00:00:00 | D |
| 3 | 4126142 | 17505157 | — | Purchase at price 4.24 per share. | MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-25 00:00:00 | D/I |
| 4 | 3536 | 15001 | — | Purchase at price 4.24 per share. | KIRBY JOHN J. | Chief Financial Officer | — | 2025-11-25 00:00:00 | D |
| 5 | 2357 | 10000 | — | Purchase at price 4.24 per share. | ROSENBERG NOAH L | Officer | — | 2025-11-25 00:00:00 | D |
| 6 | 4315 | 2805 | — | Sale at price 0.65 per share. | HAYES CHRISTOPHER G | Officer | — | 2025-03-17 00:00:00 | D |
| 7 | 450000 | — | — | Stock Gift at price 0.00 per share. | MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-26 00:00:00 | D |
| 8 | 280898 | 279353 | — | Purchase at price 0.99 per share. | RIEGER JAYSON | Chief Executive Officer | — | 2024-11-22 00:00:00 | D |
| 9 | 22921348 | 22795281 | — | Purchase at price 0.99 per share. | MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-22 00:00:00 | D/I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -63.17M | -59.66M | -20.16M | -30.31M |
| TotalUnusualItems | -2.73M | -2.54M | -1.44M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -2.73M | -2.54M | -1.44M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -76.58M | -67.00M | -24.49M | -35.08M |
| ReconciledDepreciation | 1.27M | 836.00K | 718.00K | 472.00K |
| ReconciledCostOfRevenue | 2.74M | 746.00K | 725.00K | 0.00 |
| EBITDA | -65.90M | -62.20M | -21.60M | -30.31M |
| EBIT | -67.17M | -63.03M | -22.32M | -30.79M |
| NetInterestIncome | -8.00M | -1.22M | -1.70M | -4.17M |
| InterestExpense | 9.41M | 3.96M | 2.17M | 4.29M |
| InterestIncome | 1.42M | 2.74M | 476.00K | 123.00K |
| NormalizedIncome | -73.85M | -64.46M | -23.05M | -35.08M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -76.58M | -67.00M | -24.49M | -35.08M |
| TotalExpenses | 73.40M | 68.35M | 30.33M | 42.91M |
| TotalOperatingIncomeAsReported | -65.92M | -65.76M | -21.30M | -30.91M |
| DilutedAverageShares | 5.18M | 4.53M | 3.42M | 2.70M |
| BasicAverageShares | 5.18M | 4.53M | 3.42M | 2.70M |
| DilutedEPS | -14.80 | -14.80 | -7.20 | -13.00 |
| BasicEPS | -14.80 | -14.80 | -7.20 | -13.00 |
| DilutedNIAvailtoComStockholders | -76.58M | -67.00M | -24.49M | -35.08M |
| NetIncomeCommonStockholders | -76.58M | -67.00M | -24.49M | -35.08M |
| NetIncome | -76.58M | -67.00M | -24.49M | -35.08M |
| NetIncomeIncludingNoncontrollingInterests | -76.58M | -67.00M | -24.49M | -35.08M |
| NetIncomeContinuousOperations | -76.58M | -67.00M | -24.49M | -35.08M |
| PretaxIncome | -76.58M | -67.00M | -24.49M | -35.08M |
| OtherIncomeExpense | -2.75M | -2.55M | -1.50M | |
| OtherNonOperatingIncomeExpenses | -17.00K | -14.00K | -58.00K | |
| SpecialIncomeCharges | -83.00K | -2.54M | -1.44M | 0.00 |
| GainOnSaleOfPPE | -83.00K | -2.54M | 0.00 | |
| OtherSpecialCharges | 1.44M | |||
| GainOnSaleOfSecurity | -2.65M | |||
| NetNonOperatingInterestIncomeExpense | -8.00M | -1.22M | -1.70M | -4.17M |
| InterestExpenseNonOperating | 9.41M | 3.96M | 2.17M | 4.29M |
| InterestIncomeNonOperating | 1.42M | 2.74M | 476.00K | 123.00K |
| OperatingIncome | -65.84M | -63.22M | -21.30M | -30.91M |
| OperatingExpense | 70.66M | 67.60M | 29.60M | 42.91M |
| ResearchAndDevelopment | 11.84M | 20.30M | 12.20M | 15.93M |
| SellingGeneralAndAdministration | 58.82M | 47.30M | 17.41M | 26.98M |
| GeneralAndAdministrativeExpense | 17.41M | 26.98M | ||
| OtherGandA | 17.41M | 26.98M | ||
| GrossProfit | 4.83M | 4.38M | 8.31M | 12.00M |
| CostOfRevenue | 2.74M | 746.00K | 725.00K | 0.00 |
| TotalRevenue | 7.57M | 5.12M | 9.03M | 12.00M |
| OperatingRevenue | 7.57M | 5.12M | 9.03M | 12.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 10.51K | 10.51K | 10.51K | 10.51K |
| OrdinarySharesNumber | 9.18M | 4.24M | 4.11M | 2.75M |
| ShareIssued | 9.19M | 4.25M | 4.12M | 2.76M |
| NetDebt | 25.94M | |||
| TotalDebt | 45.94M | 45.51M | 1.53M | 43.41M |
| TangibleBookValue | -9.86M | 19.76M | 40.03M | 32.60M |
| InvestedCapital | 34.06M | 62.64M | 40.03M | 74.30M |
| WorkingCapital | 22.17M | 60.51M | 35.66M | 28.27M |
| NetTangibleAssets | -9.86M | 19.76M | 40.03M | 32.60M |
| CapitalLeaseObligations | 2.02M | 2.64M | 1.53M | 1.72M |
| CommonStockEquity | -9.86M | 19.76M | 40.03M | 32.60M |
| TotalCapitalization | 21.12M | 62.64M | 40.03M | 32.60M |
| TotalEquityGrossMinorityInterest | -9.86M | 19.76M | 40.03M | 32.60M |
| StockholdersEquity | -9.86M | 19.76M | 40.03M | 32.60M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -29.00K | ||
| OtherEquityAdjustments | -29.00K | |||
| TreasuryStock | 0.00 | 0.00 | 0.00 | 0.00 |
| RetainedEarnings | -307.03M | -230.45M | -163.45M | -138.97M |
| AdditionalPaidInCapital | 297.16M | 250.21M | 203.48M | 171.60M |
| CapitalStock | 9.00K | 4.00K | 4.00K | 3.00K |
| CommonStock | 9.00K | 4.00K | 4.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 63.99M | 61.83M | 4.69M | 47.52M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 34.98M | 44.81M | 1.23M | 1.47M |
| DerivativeProductLiabilities | 2.65M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 32.33M | 44.81M | 1.23M | 1.47M |
| LongTermCapitalLeaseObligation | 1.35M | 1.94M | 1.23M | 1.47M |
| LongTermDebt | 30.98M | 42.87M | ||
| CurrentLiabilities | 29.01M | 17.02M | 3.46M | 46.05M |
| OtherCurrentLiabilities | 105.00K | 244.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 13.61M | 700.00K | 297.00K | 41.94M |
| CurrentCapitalLeaseObligation | 667.00K | 700.00K | 297.00K | 251.00K |
| CurrentDebt | 12.94M | 41.69M | ||
| OtherCurrentBorrowings | 12.94M | 41.69M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.17M | 3.44M | 1.40M | 1.67M |
| CurrentProvisions | 10.32M | 5.36M | ||
| PayablesAndAccruedExpenses | 3.81M | 7.29M | 1.76M | 2.44M |
| CurrentAccruedExpenses | 1.92M | 4.82M | 1.26M | 1.60M |
| InterestPayable | 0.00 | 250.00K | ||
| Payables | 1.90M | 2.46M | 507.00K | 845.00K |
| AccountsPayable | 1.90M | 2.46M | 507.00K | 845.00K |
| TotalAssets | 54.13M | 81.60M | 44.72M | 80.12M |
| TotalNonCurrentAssets | 2.96M | 4.07M | 5.61M | 5.80M |
| OtherNonCurrentAssets | 376.00K | 452.00K | 276.00K | 295.00K |
| NetPPE | 2.58M | 3.62M | 5.33M | 5.50M |
| AccumulatedDepreciation | -1.26M | -1.17M | -699.00K | -254.00K |
| GrossPPE | 3.84M | 4.79M | 6.03M | 5.76M |
| Leases | 54.00K | 54.00K | 54.00K | 49.00K |
| ConstructionInProgress | 0.00 | 2.54M | 2.73M | |
| OtherProperties | 1.15M | 1.41M | ||
| MachineryFurnitureEquipment | 1.79M | 2.17M | 2.00M | 1.37M |
| BuildingsAndImprovements | 836.00K | 1.16M | 1.44M | 1.61M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 51.18M | 77.53M | 39.12M | 74.33M |
| OtherCurrentAssets | 2.31M | 2.54M | 4.36M | 3.97M |
| PrepaidAssets | 3.97M | |||
| Inventory | 2.46M | 1.02M | 0.00 | |
| FinishedGoods | 717.00K | 115.00K | 0.00 | |
| WorkInProcess | 664.00K | 487.00K | 0.00 | |
| RawMaterials | 1.08M | 420.00K | 0.00 | |
| Receivables | 77.00K | 4.42M | 487.00K | 0.00 |
| OtherReceivables | 29.00K | 168.00K | 99.00K | |
| AccountsReceivable | 48.00K | 4.25M | 388.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 46.33M | 69.55M | 34.27M | 70.35M |
| OtherShortTermInvestments | 0.00 | 54.60M | ||
| CashAndCashEquivalents | 46.33M | 69.55M | 34.27M | 15.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -60.95M | -38.94M | -18.95M | -28.46M |
| RepaymentOfDebt | -2.06M | -23.00K | -43.75M | -5.00K |
| IssuanceOfDebt | 0.00 | 44.10M | 0.00 | 4.97M |
| IssuanceOfCapitalStock | 39.64M | 30.30M | 26.90M | 28.12M |
| CapitalExpenditure | -27.00K | -362.00K | -302.00K | -883.00K |
| InterestPaidSupplementalData | 7.23M | 3.15M | 1.79M | 2.85M |
| EndCashPosition | 46.33M | 69.55M | 34.27M | 15.75M |
| BeginningCashPosition | 69.55M | 34.27M | 15.75M | 10.69M |
| ChangesInCash | -23.22M | 35.27M | 18.52M | 5.07M |
| FinancingCashFlow | 37.73M | 74.21M | -16.87M | 33.65M |
| CashFlowFromContinuingFinancingActivities | 37.73M | 74.21M | -16.87M | 33.65M |
| NetOtherFinancingCharges | -176.00K | -17.00K | ||
| ProceedsFromStockOptionExercised | 155.00K | 7.00K | 0.00 | 558.00K |
| NetCommonStockIssuance | 39.64M | 30.30M | 26.90M | 28.12M |
| CommonStockIssuance | 39.64M | 30.30M | 26.90M | 28.12M |
| NetIssuancePaymentsOfDebt | -2.06M | 44.08M | -43.75M | 4.97M |
| NetShortTermDebtIssuance | -43.75M | 4.97M | ||
| ShortTermDebtPayments | -43.75M | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | 4.97M | ||
| NetLongTermDebtIssuance | -2.06M | 44.08M | -43.75M | -5.00K |
| LongTermDebtPayments | -2.06M | -23.00K | -43.75M | -5.00K |
| LongTermDebtIssuance | 0.00 | 44.10M | 0.00 | |
| InvestingCashFlow | -19.00K | -362.00K | 54.04M | -998.00K |
| CashFlowFromContinuingInvestingActivities | -19.00K | -362.00K | 54.04M | -998.00K |
| NetOtherInvestingChanges | -180.00K | -201.00K | ||
| NetInvestmentPurchaseAndSale | 0.00 | 54.34M | 86.00K | |
| SaleOfInvestment | 0.00 | 59.01M | 69.00M | |
| PurchaseOfInvestment | 0.00 | -4.67M | -68.91M | |
| NetPPEPurchaseAndSale | -19.00K | -362.00K | -302.00K | -883.00K |
| SaleOfPPE | 8.00K | 0.00 | ||
| PurchaseOfPPE | -27.00K | -362.00K | -302.00K | -883.00K |
| OperatingCashFlow | -60.93M | -38.58M | -18.65M | -27.58M |
| CashFlowFromContinuingOperatingActivities | -60.93M | -38.58M | -18.65M | -27.58M |
| ChangeInWorkingCapital | 2.03M | 9.86M | -1.80M | -535.00K |
| ChangeInOtherWorkingCapital | -500.00K | |||
| ChangeInOtherCurrentLiabilities | -322.00K | -291.00K | -264.00K | -197.00K |
| ChangeInPayablesAndAccruedExpense | -862.00K | 13.49M | -593.00K | 705.00K |
| ChangeInAccruedExpense | -294.00K | 11.29M | -255.00K | 208.00K |
| ChangeInPayable | -568.00K | 2.20M | -338.00K | 497.00K |
| ChangeInAccountPayable | -568.00K | 2.20M | -338.00K | 497.00K |
| ChangeInPrepaidAssets | -1.13M | 587.00K | -456.00K | -543.00K |
| ChangeInReceivables | 4.34M | -3.93M | -487.00K | 0.00 |
| ChangesInAccountReceivables | 4.20M | -3.86M | 0.00 | |
| OtherNonCashItems | 2.21M | 810.00K | 389.00K | 1.44M |
| StockBasedCompensation | 7.16M | 14.38M | 4.99M | 6.05M |
| AssetImpairmentCharge | 255.00K | 0.00 | ||
| AmortizationOfSecurities | 0.00 | 108.00K | 66.00K | |
| DepreciationAmortizationDepletion | 1.27M | 836.00K | 718.00K | 472.00K |
| DepreciationAndAmortization | 1.27M | 836.00K | 718.00K | 472.00K |
| Depreciation | 1.27M | 836.00K | 718.00K | 472.00K |
| OperatingGainsLosses | 2.73M | 2.54M | 1.44M | |
| GainLossOnInvestmentSecurities | 2.65M | |||
| GainLossOnSaleOfPPE | 83.00K | 2.54M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -76.58M | -67.00M | -24.49M | -35.08M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VRCA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|